References
- Ciechanover A. Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Neurodegener Dis 2012;10:7–22
- Weissman AM, Shabek N, Ciechanover A. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat Rev Mol Cell Biol 2011;12:605–20. Erratum in Nat Rev Mol Cell Biol 2011;12:686
- Lipkowitz S, Weismann AM. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer 2011;11:629–43
- Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 2007;107:687–717
- Nalepa G, Rolfe, M, Harper, JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006;5:596–613
- Lowe J, Stock D, Jap B, et al. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995;268:533–9
- Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997;386:463–71
- Abu-Baker A, Messaed C, Laganiere Gaspar JC, et al. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum Mol Genet 2003;12:2609–23
- Attaix D, Combaret L, Tilignac T, Taillandier D. Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia. Mol Biol Rep 1999;26:77–82
- Chen M, von Mikecz A. Proteasomal processing of nuclear autoantigens in systemic autoimmunity. Autoimmun Rev 2005;4:117–22
- Kumatory Tanaka AK, Inamura N, et al. Abnormally high expression of proteasomes in human leukemic cells. PNAS 1990;87:7071–5
- Rolfe M, Chiu M, Pagano MI. The ubiquitin-mediated proteolytic pathway as a therapeutic area. J Mol Med 1997;75:5–17
- Sippl W, Collura V, Colland F. Ubiquitin-specific proteases as cancer drug targets. Future Oncol 2011;7:619–32
- Mitsiades CS, Mitsiades N, Hideshima T, et al. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets 2006;7:1341–7
- Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630–9
- Iqbal M, Chatterjee S, Kauer JC, et al. Potent inhibitors of proteasome. J Med Chem 1995;38:2276–7
- Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967;118:157–62
- Iqbal M, Diebold JL, Siman R, et al. Multicatalytic protease inhibitors. US Patent 1999; 5,990,083:1--48
- Chatterjee S, Ator MA, Bozyczko-Coyne D, et al. Synthesis and biological activity of a series of potent fluoromethyl ketone inhibitors of recombinant human calpain I. J Med Chem 1997;40:3820–8